Jia Bing

Associate Professor; Doctoral Supervisor

Contact Information

Email: jiabing@bjmu.edu.cn

Office: Central Laboratory Building, Room 220

Personal Profile

Since helping establish the Peking University Medical Isotope Research Center in 2001, Prof. Jia has focused on radiopharmaceutical molecular imaging agents and targeted radionuclide therapy for cancer. He has led five projects funded by the National Natural Science Foundation of China (NSFC) and one by the Beijing Natural Science Foundation. As a sub-project lead or participant, he has contributed to one project each under the Ministry of Science and Technology’s “973 Program,” the “Major New Drug Discovery” initiative, and the NSFC Major Scientific Instrument Development program. He holds 18 granted Chinese invention patents, two of which have been commercially transferred and are each advancing toward Class I new drug applications. He has published 100+ papers, including 89 SCI-indexed articles. In 2023, he received the Ministry of Education Technological Invention Award (Special Prize).

Research Interests

Radiopharmaceuticals

Molecular imaging in oncology

Targeted radionuclide therapy

Academic Service

Board Member, Isotope Division, Chinese Nuclear Society

Executive Board Member, Radiopharmaceutical Division, Chinese Nuclear Society

Selected Publications (Past Five Years)

1. A Novel PSMA/FAP-Specific Radiotracer ^99mTc-HFaPSMA for Diagnosis of Wang Y, Li X, Li C, Xing H, Gao R, Jia B*. PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation.  J Med Chem . 2025, 28;68(16):17598-17610

2. Li C, Li X, Wang Y, Bai Z, Wang Y, Gao R, Jia B*. Technetium-99m-Labeled Fibroblast Activation Protein-Targeted Nanobody Radiotracer: from Preclinical Development to Clinical Translation in Cancer Imaging.  ACS Pharmacol Transl Sci . 2025, 8(8):2673-2682.

3. Zhou X^#, Yan S^#, Ma X, Zhu H, Liu B, Yang X, Jia B*, Yang Z*, Wu N*, Li N*. Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer.  Eur J Nucl Med Mol Imaging . 2025, 52(7): 2343-2354.

4. Ma X^#, Hu B^#, Zhou X, Wang L, Chen H, Xie F, Zhu H*, Jia B*, Yang Z*. Development and First-in-Human evaluation of a Site-Specific [¹⁸F]-Labeled PD-L1 nanobody PET radiotracer for noninvasive imaging in NSCLC.  Bioorg Chem . 2025,156:108222

5. Bai Z^#, Xie X^#, Li C, Wang Y, Wang Y, Li H, Gao R*, Jia B*. Claudin18.2-Targeted SPECT/CT Imaging for Gastric Cancer: Preclinical Evaluation and Clinical Translation of the ^99mTc-Labeled Nanobody (PHG102) Radiotracer.  Acs Pharmacol Transl . 2024, 7(8):2465-2475

6. Wang R^#, Bai Z^#, Zhong W^#, Li C, Wang J, Xiang J, Du J*, Jia B*, Zhu Z*. Synthesis, preclinical evaluation and pilot clinical translation of [⁶⁸Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer.  Eur J Nucl Med Mol Imaging . 2024, 51(12):3731-3743

7. Hu B, Ma X, Shi L, Liu T, Li L, Yao M, Li C, Jia B*. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel ^99mTc-Labeled Nanobody Tracer with Rapid Renal Clearance.  Mol Pharm . 2024, 21(4):1977-1986.

8. Ma M^#, Yang G^#, Zhao M, Liu Y, Ge X, Jia B*, Gao S*. Synthesis and Preliminary Study of ^99mTc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors.  Mol Pharm . 2024, 21(2):735-744

9. Xie B^#, Li L^#, Lin M^#, Nanna M, Su Y, Hua C, Leng C, Gan Q, Xi XY, Wang Y, Yao D, Wang L, Yu L, Zhao L, Zhang YP, Dou K, Su P, Lv X*, Jia B*, Yang MF*. ^99mTc-HFAPi imaging identifies early myocardial fibrosis in the hypertensive heart.  J Hypertens . 2023, 41(10):1645-1652

10. Ma X^#, Zhou X^#, Hu B^#, Li X, Yao M, Li L, Qin X, Li D, Yao Y, Hou X, Liu S, Chen Y, Wang Z, Zhou W, Li N*, Zhu H*, Jia B*, Yang Z*. Preclinical evaluation and pilot clinical study of [⁶⁸Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging.  Eur J Nucl Med Mol Imaging . 2023, 50(13):3838-3850

11. Jia X^#, Li X^#, Jia B^#, Yang Y, Wang Y, Liu Y, Ji T, Xie X, Yao Y, Qiu G, Deng H, Zhu Z, Chen S, Yang A, Gao R*. The role of [^99mTc]Tc-HFAPi SPECT/CT in patients with malignancies of digestive system: first clinical experience.  Eur J Nucl Med Mol Imaging . 2023, 50(4):1228-1239

12. Qin X, Guo X, Liu T, Li L, Zhou N, Ma X, Meng X, Liu J, Zhu H*, Jia B*, Yang Z*. High in-vivo stability in preclinical and first-in-human experiments with [¹⁸F]AlF-RESCA-MIRC213: a ¹⁸F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers.  Eur J Nucl Med Mol Imaging . 2023, 50(2):302-313

13. Li L, Liu T, Shi L, Zhang X, Guo X, Hu B, Yao M, Zhu H, Yang Z, Jia B*, Wang F. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.  Theranostics . 2022, 12(12):5551-5563.

14. Shi L, Chen B, Liu T, Li L, Hu B, Li C, Jia B*, Wang F*. ^99mTc-CD3813: A Nanobody-Based Single Photon Emission Computed Tomography Radiotracer with Clinical Potential for Myeloma Imaging and Evaluation of CD38 Expression.  Mol Pharm . 2022, 19(7):2583-2594

15. Hu B, Liu T, Li L, Shi L, Yao M, Li C, Ma X, Zhu H, Jia B*, Wang F. IgG-Binding Nanobody Capable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life and Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy.  Bioconjug Chem . 2022, 33(7):1328-1339.

16. Liu T, Wu Y, Shi L, Li L, Hu B, Wang Y, Gao H, Yu X, Zhang X, Zhao H, Wan Y, Jia B*, Wang F*. Preclinical evaluation of [^99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT.  Eur J Nucl Med Mol Imaging . 2022, 49(6):1810-1821

17. Zhang X, Chen M, Zhang Y, Hou Y, Wu Y, Yao M, Li L, Shi L, Liu T, Hu B, Zhao H, Li X, Shi J, Jia B*, and Wang F. Monoclonal-Antibody-Templated Gold Nanoclusters for HER2 Receptors Targeted Fluorescence Imaging.  ACS Appl Bio Mater . 2020, 3, 10, 7061–7066.

18. Gao S^#, Jia B^#, Feng G^#, Dong C^#, Du H, Bai L, Zhong Q, Ma Q, Zeng M, Wang F*. First-in-human Pilot Study of an Integrin α6-targeted Radiotracer for SPECT Imaging of Breast Cancer.  Signal Transduct Target Ther . 2020, 5(1):147